In Vitro PHA Monomer Synthesis for Homogeneous Long-Chain Polymers

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for producing polyhydroxyalkanoate (PHA) polymers are limited to C1-C8 chain lengths and often require purification, failing to provide homogeneous, straight chain PHAs suitable for consumer and industrial applications, and lack the ability to produce a wide range of chain lengths.

Innovation Solution

An enzymatic process that utilizes a combination of enzymes to convert long-chain fatty acids or their precursors into homogeneous polyhydroxyalkanoate monomers and polymers with chain lengths of at least eight carbons, allowing for the production of novel PHAs without the need for purification or separation, and enabling the creation of copolymers through the use of multiple substrate species.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If existing bacterial methods are used to produce PHA polymers, then production is achieved, but the chain length is limited to C1-C8 and purification is required

Engineering Contradiction:

Improvechain length controlVSAvoidchain length range

Core Design Contradiction:

Manufacturing precisionVSAdaptability or versatility

Solution Approach 1:

The patent replaces the biological/bacterial system with an in vitro enzymatic system. By using purified enzymes (PhaA, PhaB, PhaC) outside of living organisms, the invention achieves precise control over the polymerization process, enabling production of PHA polymers with chain lengths exceeding C8 while eliminating the need for purification steps that were required in bacterial systems.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The invention changes the fundamental parameters of the synthesis system by transitioning from in vivo bacterial metabolism to in vitro enzymatic reactions. This parameter change allows for extended chain lengths (beyond C8) and homogeneous product formation without the metabolic constraints and side reactions that limit bacterial systems.

Inventive Principle:

Principle #35Parameter changes

2Stability of the object's composition

If existing PHA synthesis methods are used, then some PHA polymers are produced, but homogeneous straight chain polymers cannot be obtained

Engineering Contradiction:

Improvepolymer homogeneityVSAvoidpurification requirement

Core Design Contradiction:

Stability of the object's compositionVSEase of manufacture

Solution Approach 1:

By replacing the complex bacterial metabolic system with a controlled in vitro enzymatic system using purified enzymes, the invention achieves homogeneous straight chain PHA polymers. The controlled environment eliminates metabolic side reactions that cause heterogeneity, and the system produces polymers that require no further purification.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces purified enzymes as intermediaries that mediate the conversion of substrates to homogeneous PHA polymers. These enzyme intermediaries (PhaA, PhaB, PhaC) ensure specific and controlled reactions that produce uniform straight chain polymers without the need for additional purification steps.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If bacterial production methods are used, then PHA polymers are synthesized, but metabolic side reactions occur

Engineering Contradiction:

ImprovePHA productionVSAvoidreaction specificity

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The invention substitutes the bacterial metabolic system with an in vitro enzymatic system, eliminating the complex metabolic pathways that cause side reactions. The purified enzymes operate with high specificity in a controlled environment, maintaining reliable and specific conversions while achieving productive PHA synthesis.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent extracts the essential enzymatic functions (PhaA, PhaB, PhaC) from the bacterial system and performs the polymerization in vitro. This extraction removes the problematic metabolic side reactions while retaining the productive polymer synthesis capability, achieving both high productivity and reaction specificity.

Inventive Principle:

Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The process efficiently produces homogeneous PHA polymers with extended chain lengths, overcoming limitations of existing methods by ensuring single molecular species and reducing the need for purification, while avoiding metabolic side reactions and microplastic generation.

Implementation Method 1

contacting a long-chain fatty acid or precursor thereof, in vitro with an enzyme or a mixture of enzymes, and producing homogeneous chain length polyhydroxyalkanoate monomers and/or polymers

Methodology Applied

Scientific EffectEnzyme catalysis: Enzyme

Data Source

PatentUS20260098283A1In Vitro Bioproduction of Specific Chain Legnth Poly(hydroxyalkanoate) Monomers

Publication Date: 2026.04.09 KIMBERLY CLARK WORLDWIDE INC

AI summary

An enzymatic process and system are disclosed for producing homogeneous chain length poly hydroxyalkanoate monomers and/or polymers having a chain length of at least eight carbons from a long-chain fatty acid or precursor thereof. The process also results in specific homogenous chain length polyhydroxyalkanoate monomers and/or polymers. The long-chain fatty acid or precursor thereof can be contacted in vitro with an enzyme or a mixture of enzymes to produce the homogeneous chain length polyhydroxyalkanoate.